-
Identification of the familial cylindromatosis tumour-suppressor gene.
Bignell GR,
Warren W,
Seal S,
Takahashi M,
Rapley E,
Barfoot R,
Green H,
Brown C,
Biggs PJ,
Lakhani SR,
Jones C,
Hansen J,
Blair E,
Hofmann B,
Siebert R,
Turner G,
Evans DG,
Schrander-Stumpel C,
Beemer FA,
van Den Ouweland A,
Halley D,
Delpech B,
Cleveland MG,
Leigh I,
Leisti J,
Rasmussen S.
[1] Section of Cancer Genetics, Institute of Cancer Research, Sutton, Surrey, UK.
Familial cylindromatosis is an autosomal dominant genetic predisposition to multiple tumours of the skin appendages. The susceptibility gene (CYLD) has previously been localized to chromosome 16q and has the genetic attributes of a tumour-suppressor gene (recessive oncogene). Here we have identified CYLD by detecting germline mutations in 21 cylindromatosis families and somatic mutations in 1 sporadic and 5 familial cylindromas. All mutations predict truncation or absence of the encoded protein. CYLD encodes three cytoskeletal-associated-protein-glycine-conserved (CAP-GLY) domains, which are found in proteins that coordinate the attachment of organelles to microtubules. CYLD also has sequence homology to the catalytic domain of ubiquitin carboxy-terminal hydrolases (UCH).
PMID: 10835629 [PubMed - indexed for MEDLINE]
-
Cited by 22 PubMed Central articles
-
Truncation of the catalytic domain of the cylindromatosis tumor suppressor impairs lung maturation.
Trompouki E, Tsagaratou A, Kosmidis SK, Dollé P, Qian J, Kontoyiannis DL, Cardoso WV, Mosialos G.
Neoplasia. 2009 May; 11(5):469-76.
[Neoplasia. 2009]
-
ReviewThe ubiquitin system, disease, and drug discovery.
Petroski MD.
BMC Biochem. 2008 Oct 21; 9 Suppl 1:S7. Epub 2008 Oct 21.
[BMC Biochem. 2008]
-
ReviewDeubiquitylating enzymes and disease.
Singhal S, Taylor MC, Baker RT.
BMC Biochem. 2008 Oct 21; 9 Suppl 1:S3. Epub 2008 Oct 21.
[BMC Biochem. 2008]
- » See all...